Envisagenics Revenue and Competitors

Location

$25.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Envisagenics's estimated annual revenue is currently $4.2M per year.(i)
  • Envisagenics's estimated revenue per employee is $77,500
  • Envisagenics's total funding is $25.1M.

Employee Data

  • Envisagenics has 54 Employees.(i)
  • Envisagenics grew their employee count by 17% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.3M6811%$3MN/A
#2
$1.4M7N/AN/AN/A
#3
$15.7M78-26%$176.6MN/A
#4
$39060M679084%$30 b$234.4B
#5
$130.9M651N/AN/AN/A
#6
$25.7M161N/AN/AN/A
#7
$124.8M9101%$567.2M$2.2B
#8
$1.2M14N/AN/AN/A
#9
$0.9M6N/AN/AN/A
#10
$2360M410111%$22.5M$10.7B
#11
$12.2M79N/AN/AN/A
#12
$275.4M112613%N/A$4.4B
#13
$11.2M7231%N/AN/A
#14
$14.8M67-24%N/AN/A
#15
$0.1M4N/AN/AN/A
#16
$2.7M27N/AN/AN/A
#17
$87.4M564N/AN/AN/A
#18
$46.5M2332%$396M$424.9M
#19
$8.4M54N/AN/AN/A
#20
$0.5M9N/AN/AN/A
Add Company

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. \n\nWe focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.\n\nOur breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

keywords:Pharmaceuticals, Bioinformatics, Genomics

$25.1M

Total Funding

54

Number of Employees

$4.2M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Envisagenics News

2022-04-17 - AI Drug Discovery Market Is Booming Worldwide ...

... Cloud Pharmaceuticals Inc, , Insilico Medicine, , Benevolentai, , Exscientia, , Cyclica, , Bioage, , Numerate, , Envisagenics, , TwoXAR,...

2021-10-01 - Envisagenics Raises Series A Financing

Envisagenics, a NYC-based Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured a Series A financing of undisclosed amount. The round was led by Red Cell Partners, with participation from Microsoft’s M12, Madron ...

2021-09-29 - Envisagenics : Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discovery platform and biopharmaceutical partnerships. Red Cell ...

2017-12-04 - AI and RNA splicing: Is Envisagenics’ $2.35M seed round a sign of what’s to come?

That last feature was a coincidence, said to Co-founder and CEO Maria Luisa Pineda. “We actually didn’t realize that until we started putting the press release together and counting [the female VCs],” Pineda said in a phone interview. Envisagenics’ round was led by Daniella Kranjac, co-founder ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.9M54-14%$39M
#2
$6.8M54-29%$71.3M
#3
$9.9M5426%$47.4M
#4
$6.8M544%N/A
#5
$6.8M54-27%N/A